HC Wainwright & Co. Reiterates Buy on Viracta Therapeutics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Viracta Therapeutics (NASDAQ:VIRX) and maintained a $4 price target.

April 16, 2024 | 2:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viracta Therapeutics maintains a Buy rating and a $4 price target from HC Wainwright & Co., as reiterated by analyst Robert Burns.
The reiteration of a Buy rating and a maintained price target of $4 by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100